Poland's journey onto our list hasn't been an easy one. After the fall of the Iron Curtain more than 20 years ago, Poland emerged with Russia as an outsourcing hot spot in Eastern Europe, but the clinical market there was stagnant during the last decade.

Now, thanks to some recent government initiatives to boost clinical research, Poland is climbing back into the outsourcing spotlight. Four years ago, the Polish government lifted a tax block, allowing clinical research to be taxable in a client's home country, rather than in Poland, according to Outsourcing-Pharma. The previous tax code comprised a confusing mix of tax classifications, some with built-in exemptions and others without.

Last year, the Polish clinical trial market exhibited 7% growth, according to a study by market research group PMR. Year-to-year expansion is expected to hover around 3% and 4% in 2012 and 2013, the study showed. One company that's planning to be part of that expansion is Synexus, which opened four Polish outposts over the past two years, thanks to acquiring Polish CRO Osteomed in May. The data aren't jaw-dropping by any means, but they do give hope to a once-dormant market.

Still, the study reinforces the fact that Poland needs to undertake some reforms if it wants to broaden its appeal for clinical research. For example, the procedure for enrolling in the Central Register of Clinical Trials is "lengthy and complicated," Outsourcing-Pharma points out.


Suggested Articles

Contract research bigwig Parexel and Vivek Ramaswamy’s Datavant are deepening their trial tech partnership with a new, multiyear deal.

Charles River signed on to an Alzheimer's UK research consortium.

John Ratliff is leaving his former post as CEO of Covance and moving up to lead the CRO’s parent company LabCorp Diagnostics amid a change at the top.